-
Medarex (former
NASDAQ symbol: MEDX ) was an
American biopharmaceutical company based in Princeton, New Jersey, with
manufacturing facilities in Bloomsbury...
-
NASDAQ Global Select Market in the US. Genmab's
technology is
licensed from
Medarex to
create fully human high
affinity antibodies using transgenic mice. These...
-
entered in 2005
between Ono and
Medarex.[citation needed]
Through the
research collaboration with Ono, it was
invented at
Medarex using its
transgenic mice...
- California, Berkeley.
Clinical development of anti-CTLA4 was
initiated by
Medarex,
which was
later acquired by Bristol-Myers Squibb. For his work in developing...
-
monoclonal antibody for
treatment for arthritis,
which was co-developed with
Medarex, Inc. In 2004, the
United States Department of
Justice began investigating...
-
during a
major restructuring activity, BMS
acquired the
biotechnology firm
Medarex as part of the company's "String of Pearls"
strategy of alliances, partnerships...
-
Martek Biosciences (1985–2011)
Mayne Pharma (2005–2007)
Maxygen (1997–2013)
Medarex (1987–2009) Meda (1995–2016)
MedImmune (1988–2019)
Mylan (1961–2019) Nycomed...
-
Archived from the
original on
April 6, 2020.
Retrieved April 6, 2020. "
Medarex to
Receive Milestone Payment for
Approval of
Stelara (Ustekinumab) for...
- was
developed through Phase II
efficacy trials by a
partnership between Medarex Inc and M****Biologics of the
University of M****achusetts
Medical School...
- is an investigational,
monoclonal antibody combination co-developed by
Medarex and M****achusetts
Biologic Laboratories (MBL) to
target and neutralize...
